title: Long-term effect of atenolol on ejection fraction, symptoms, and exercise variables in patients with advanced left ventricular dysfunction.
abstract: OBJECTIVE
  We recently reported a beneficial clinical effect of atenolol, a beta(1) selective adrenergic antagonist, in 100 ambulatory heart failure patients with low left ventricular ejection fraction (LVEF, <or=25%) who were receiving background therapy with 40 mg/day enalapril. In this sub-study, we investigated the effects of atenolol vs placebo on LVEF, New York Heart Association (NYHA) class, workload, and peak oxygen consumption (Vo(2)).
  
  
  RESULTS
  We included 43 patients (23 receiving atenolol, 20 receiving placebo) who had similar entry characteristics. We evaluated LVEF once a year and evaluated workload, pVO(2), and NYHA class before and after 6, 12, and 24 months. Repeated measures of analysis of variance were used for comparison of serial measurements. After 2 years, both atenolol (18% +/- 5% vs 36% +/- 18%, p < 0.05) and placebo (18% +/- 5% vs 23% +/- 5%, p < 0.05) increased LVEF, with a more pronounced effect of atenolol (p = 0.02), which also changed NYHA class distribution more favorably over time (p < 0.05). Workload and peak Vo(2) increased after atenolol (110 +/- 47 vs 140 +/- 48 watts, p < 0.05, and 18 +/- 5 vs 21 +/- 5 ml/kg/min, p < 0.05) but not after placebo (100 +/- 35 vs 110 +/- 38 watts, p < 0.05, between groups and 17 +/- 4 vs 19 +/- 7 ml/kg/min, not significant, between groups).
  
  
  CONCLUSIONS
  In patients with advanced heart failure who tolerate long-term atenolol vs placebo treatment added to high-dose enalapril for 2 years without cardiac events, systolic left ventricular function is markedly improved. These patients experience greater relief of symptoms and increased exercise tolerance.
authors.affiliation: Department of Cardiology, Ludwig Boltzmann Institute for Cardiovascular Research, University of Vienna, Vienna, Austria. martin.huelsmann@univie.ac.at
authors.forename: M
authors.initials: M
authors.lastname: Hülsmann
authors.forename: B
authors.initials: B
authors.lastname: Sturm
authors.forename: R
authors.initials: R
authors.lastname: Pacher
authors.forename: R
authors.initials: R
authors.lastname: Berger
authors.forename: A
authors.initials: A
authors.lastname: Bojic
authors.forename: B
authors.initials: B
authors.lastname: Frey
authors.forename: B
authors.initials: B
authors.lastname: Stanek
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage / Q000494:pharmacology*; D001262:Atenolol / Q000008:administration & dosage / Q000494:pharmacology*; D004311:Double-Blind Method; D004656:Enalapril / Q000008:administration & dosage; D005080:Exercise Test; D017079:Exercise Tolerance / Q000187:drug effects*; D006801:Humans; D010101:Oxygen Consumption / Q000187:drug effects; D011446:Prospective Studies; D013318:Stroke Volume / Q000187:drug effects*; D018487:Ventricular Dysfunction, Left / Q000188:drug therapy / Q000503:physiopathology*
chemical_list: D000319:Adrenergic beta-Antagonists; D001262:Atenolol; D004656:Enalapril